📞 
— free, 24/7
— free, 24/7 — free, 24/7| Dosage | Package | Price per Dose | Price | |
|---|---|---|---|---|
| 0,5mg | 270 pills | £0.67 | £259.96 £181.98 Popular | |
| 0,5mg | 360 pills | £0.49 | £253.55 £177.48 Best Price | |
| 0,5mg | 180 pills | £0.85 | £219.84 £153.89 | |
| 0,5mg | 120 pills | £1.12 | £192.56 £134.79 | |
| 0,5mg | 90 pills | £1.28 | £165.28 £115.70 | |
| 0,5mg | 60 pills | £1.49 | £128.37 £89.86 |
This information is intended to support discussions with a healthcare professional. It does not replace advice from a clinician or pharmacist.
Colchicine is a medicine belonging to the alkaloid class, derived from the autumn crocus (Colchicum autumnale). The active ingredient is colchicine itself. It is prescribed to treat certain inflammatory conditions by reducing the activity of inflammatory cells in affected tissues.
In the United Kingdom, colchicine may be prescribed for acute gout attacks, for familial Mediterranean fever (FMF), and for pericarditis and its recurrence prevention. Its use may be short term during an attack or longer term for ongoing management in some conditions, as directed by a clinician. The aim is to lessen pain, swelling and other inflammatory symptoms associated with these conditions.
Colchicine is available in tablet form and may be supplied as part of a treatment plan by a clinician or pharmacist. The medication is intended to be used under medical supervision, with monitoring to ensure safety and effectiveness. This information covers how colchicine works, how to take it, and safety considerations for adults and, where appropriate, certain children.
Colchicine should be used strictly according to the prescriber’s instructions. If questions arise about suitability, dosing, or duration, discussion with a pharmacist or clinician is advised.
Gout is a form of inflammatory arthritis caused by the formation of uric acid crystals in joints, often presenting with sudden, severe joint pain and swelling. It frequently affects the big toe but can involve other joints as well. Colchicine can help reduce inflammation during a flare and relieve symptoms in many patients.
Familial Mediterranean fever (FMF) is an inherited autoinflammatory disorder characterised by recurrent fever episodes and painful inflammation in different parts of the body. Colchicine is used to reduce the frequency of attacks and to prevent long-term complications in some individuals.
Pericarditis refers to inflammation of the lining around the heart, which can cause chest pain and shortness of breath. Colchicine may be used to treat acute pericarditis and to help prevent recurrence in selected cases, as advised by a clinician. It is not a cure for all cases, but may help in conjunction with other therapies.
Other inflammatory conditions may be treated with colchicine when a clinician considers it appropriate. The decision to use colchicine in these conditions depends on clinical judgment and individual risk–benefit assessment.
Colchicine binds to tubulin, a protein that forms microtubules within cells. This interaction interferes with the ability of cells to form these structural components. The disruption of microtubule formation affects cellular processes that are important in inflammation and cell movement.
As a result, the activity of neutrophils (a type of white blood cell involved in inflammatory responses) is reduced. This leads to a decrease in inflammatory reactions at sites such as joints or serous membranes, which can relieve pain and swelling during a flare.
The overall anti-inflammatory effect is influenced by the condition being treated and by how colchicine is used in combination with other treatments. The full mechanism is complex and may vary between individuals. Treatment plans are tailored by clinicians to balance benefits with potential risks.
Colchicine is not a universal remedy for all inflammatory conditions; its use is guided by clinical indications, patient health status, and monitoring for adverse effects. Ongoing assessment by a healthcare professional is recommended during therapy.
Colchicine should be taken exactly as prescribed. The aim is to use the lowest effective dose for the shortest necessary duration, in order to minimise side effects while achieving symptom relief. If dosing is uncertain, a clinician or pharmacist should be consulted before taking additional amounts.
Timing and duration depend on the condition being treated. Some regimens involve an initial higher dose followed by a lower maintenance dose, while others use a simpler schedule. The prescriber will provide specific instructions based on the indication and patient factors.
Colchicine can be taken with or without food. If gastrointestinal upset occurs, taking tablets with meals may help to reduce discomfort. Adequate hydration is recommended unless advised otherwise by a clinician, as dehydration can affect tolerability and safety.
If a dose is missed, the next dose should be taken at the usual scheduled time. Do not double the next dose to make up for the missed one. If several doses are missed or if there is any uncertainty, seek guidance from a healthcare professional promptly.
Colchicine should not be taken by individuals with a known allergy to colchicine or to any component of the product. An allergic reaction requires immediate medical attention.
Severe kidney or liver disease increases the risk of adverse effects and may require adjustment of treatment or an alternative therapy. A clinician should review liver and kidney function before and during treatment if these conditions are present.
Active infections with dehydration, certain blood disorders, or significant gastrointestinal disease may preclude use. In these situations a clinician will assess whether colchicine is appropriate and may suggest alternative treatments.
Pregnancy and breastfeeding require careful consideration. The decision to use colchicine during pregnancy or while breastfeeding should be discussed with a clinician, taking into account potential benefits and risks for both mother and baby.
Monitoring is advised in older adults and in those with known kidney or liver impairment. Regular review helps to ensure that the treatment remains appropriate and safe. Any new symptoms should be reported promptly to a clinician.
Gastrointestinal side effects such as diarrhoea, nausea, and vomiting are common, especially at the start of therapy. These symptoms often improve with continued treatment or dose adjustments under medical supervision. Severe or persistent GI symptoms should be discussed with a healthcare professional.
Muscle pain, weakness, numbness, or dark urine may indicate muscle toxicity or other serious adverse effects. If these symptoms occur, urgent medical advice should be sought. Informing healthcare providers about all medicines being taken is important to manage potential risks.
Interactions with other medicines can alter colchicine levels or increase toxicity. A comprehensive review of current medicines, including over‑the‑counter drugs and herbal supplements, is recommended before starting therapy. Hydration and avoidance of dehydration are useful preventative measures where appropriate.
Colchicine commonly causes gastrointestinal symptoms, particularly early in treatment. These effects include stomach upset, nausea, vomiting, and diarrhoea in some individuals. They may subside over time or with dose adjustments under supervision.
Muscle-related symptoms such as pain or weakness can occur, especially when combined with certain other medicines. Monitoring for these signs is important, and discontinuation or modification may be required if they arise.
Less common effects may include headache, dizziness, or skin rashes. If any new or persistent symptoms occur, a clinician or pharmacist should be consulted. Seek urgent medical care if signs of an allergic reaction develop (such as swelling of the face or throat, severe rash, or trouble breathing).
A number of medicines, foods and supplements can interact with colchicine and may increase the chance of adverse effects or reduce effectiveness. It is essential to discuss all current medicines with a clinician or pharmacist before starting therapy.
Major interactions involve medicines that affect the body’s ability to metabolise colchicine, including certain antibiotics and antifungals, and some medicines used to suppress the immune system. These interactions can lead to higher colchicine levels in the blood and increase the risk of toxicity.
Other medicines such as some heart medicines and cholesterol-lowering agents may interact with colchicine. Foods like grapefruit juice can influence the way colchicine is processed in the body. Herbal or over‑the‑counter products may also interact, so disclosure to a healthcare professional is advised.
To help manage interactions, a clinician will review a patient’s complete medication list, including non-prescription products and supplements. If any new medicine is started, informed discussion with a healthcare professional is recommended to assess potential interactions.
Safety in pregnancy has not been established for all indications, and colchicine use during pregnancy should be considered only if clearly needed and after specialist consultation. The potential benefits and risks must be weighed carefully by a clinician.
In some scenarios, colchicine may be prescribed during pregnancy under close supervision, but this requires careful assessment. The decision rests on individual circumstances and clinical judgment.
Colchicine passes into breast milk, and the effects on a breastfeeding infant are not fully known in all situations. Breastfeeding while taking colchicine should be discussed with a clinician to determine whether continued treatment is appropriate. If pregnancy is planned, the prescriber should be informed before starting therapy.
Any changes to pregnancy status or plans should be communicated promptly to a healthcare professional to re‑evaluate the treatment plan.
Response to treatment can vary by individual and condition. Some patients notice changes within a day or two, while others may require a longer period or additional therapies. If there is no meaningful improvement within the expected time frame, a clinician should be consulted.
Do not double the next dose to make up for a missed one. If a dose is missed, take the next scheduled dose at the usual time. If several doses have been missed, contact a clinician for guidance.
Colchicine can be taken with or without food. Taking it with meals may help reduce gastrointestinal upset in some individuals. The use of alcohol should be discussed with a clinician, as it may influence symptoms or side effects in certain cases.
Duration depends on the condition treated. Acute gout regimens are usually short term, while FMF or pericarditis may require longer treatment under medical supervision. Ongoing use should be reviewed regularly by a clinician.
Medical advice should be sought if persistent or severe side effects occur, if there are signs of muscle toxicity (such as muscle pain or weakness), or if symptoms worsen or fail to improve. Seek urgent medical help if any signs of an allergic reaction appear.
Long-term use may be required for certain conditions, but it carries an increased risk of adverse effects. Regular monitoring by a clinician is essential to assess safety and effectiveness and to adjust the plan as needed.
Muscle pain or weakness can indicate toxicity, particularly when taken with other medicines that affect muscles. A clinician should be informed promptly to determine whether the treatment should be continued, paused, or adjusted.
Pregnancy planning and pregnancy status should be disclosed to a clinician before starting colchicine. In certain scenarios, treatment may proceed under specialist supervision, while in others alternative therapies may be considered.
Yes; interactions can occur with many non-prescription products. Disclosure to a clinician or pharmacist is essential before starting or continuing therapy, to ensure safety and avoid adverse effects.
Overdose requires urgent medical attention. If an overdose is suspected, seek medical help promptly or contact local emergency services. Early treatment can reduce the risk of serious harm.
Additional information is available in the official patient information leaflet supplied with the medicine and through consultation with a pharmacist or clinician. Official guidelines and product information may be accessible through NHS resources or the device of the prescription, as advised by a healthcare professional.
Official patient information leaflets (PILs) accompany the medication and provide detailed instructions, safety information, and warnings. These leaflets are a primary source for patient-facing guidance and should be consulted alongside professional advice.
Additional information may be available from the Medicines and Healthcare products Regulatory Agency (MHRA), the National Health Service (NHS), and other official health resources. The information provided by these sources should be used to support, not replace, discussions with a clinician.
A pharmacist or general practitioner can answer questions about side effects, interactions with other medicines, and appropriate use in specific circumstances. When concerns arise regarding dosing, potential interactions, or changes in health status, a prompt consultation is recommended.
If access to printed materials is limited, ask a pharmacist for a current official leaflet or for advice on where to obtain the most up-to-date information. The safest approach involves verified guidance from a qualified healthcare professional.
14–21 days. Free from £149.78 .
5–9 days. £22.47
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
